The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Open accessAbstract
PURPOSE: Many patients with HR+, HER2− early breast cancer (EBC) will not experience recurrence or have distant recurrence with currently available standard therapies. However, up to 30% of patients with high-risk clinical and/or pathologic features may experience distant recurrence, many in the first few years. Superior treatment options are needed to prevent early recurrence and development of metastases for this group of patients. Abemaciclib is an oral, continuously dosed, CDK4/6 inhibitor approved for HR+, HER2− advanced breast cancer (ABC). Efficacy and safety of abemaciclib in ABC supported evaluation in the adjuvant setting. METHODS: This open-label, phase III study included patients with HR+, HER2−, high-risk EBC, who had surgery and, as indicated, radiotherapy and/or adjuvant/neoadjuvant chemotherapy. Patients with four or more positive nodes, or one to three nodes and either tumor size ≥ 5 cm, histologic grade 3, or central Ki-67 ≥ 20%, were eligible and randomly assigned (1:1) to standard-of-care adjuvant endocrine therapy (ET) with or without abemaciclib (150 mg twice daily for 2 years). The primary end point was invasive disease-free survival (IDFS), and secondary end points included distant relapse–free survival, overall survival, and safety. RESULTS: At a preplanned efficacy interim analysis, among 5,637 randomly assigned patients, 323 IDFS events were observed in the intent-to-treat population. Abemaciclib plus ET demonstrated superior IDFS versus ET alone ( P = .01; hazard ratio, 0.75; 95% CI, 0.60 to 0.93), with 2-year IDFS rates of 92.2% versus 88.7%, respectively. Safety data were consistent with the known safety profile of abemaciclib. CONCLUSION: Abemaciclib when combined with ET is the first CDK4/6 inhibitor to demonstrate a significant improvement in IDFS in patients with HR+, HER2− node-positive EBC at high risk of early recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., Fitzgibbons, P., Hanna, W., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8738 · Cited by 2,435
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Cardoso, F., van’t Veer, L. J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., Pierga, J.-Y., Brain, E., Causeret, S., DeLorenzi, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602253 · Cited by 1,994
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
Self-citationSledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680 · cited 5×
“This intriguing observation has been reported previously in a randomized study of a CDK4/6 inhibitor plus ET.20 The most frequently reported AE in the abemaciclib arm was diarrhea.”
InfluentialSelf-citationCuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., Zackrisson, S., & Cardoso, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv298 · Cited by 1,597
(2015) · The Lancet · doi:10.1016/s0140-6736(15)61074-1 · Cited by 1,520
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.4782 · Cited by 991
Self-citation(2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70385-6 · Cited by 919
Hudis, C. A., Barlow, W. E., Costantino, J. P., Gray, R. J., Pritchard, K. I., Chapman, J.-A. W., Sparano, J. A., Hunsberger, S., Enos, R. A., Gelber, R. D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3523 · Cited by 864
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Johnston, S., Martin, M., Di Leo, A., Im, S.-A., Awada, A., Forrester, T., Frenzel, M., Hardebeck, M. C., Cox, J., Barriga, S., et al. (2019) · npj Breast Cancer · doi:10.1038/s41523-018-0097-z · Cited by 685
Self-citationDickler, M. N., Tolaney, S. M., Rugo, H. S., Cortés, J., Diéras, V., Patt, D., Wildiers, H., Hudis, C. A., O'Shaughnessy, J., Zamora, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0754 · Cited by 676
Self-citationHammond, M. E. H., Hayes, D. F., Wolff, A. C., Mangu, P. B., & Temin, S. (2010) · Journal of Oncology Practice · doi:10.1200/jop.777003 · Cited by 583
Gluz, O., Nitz, U. A., Christgen, M., Kates, R. E., Shak, S., Clemens, M., Kraemer, S., Aktas, B., Kuemmel, S., Reimer, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5383 · Cited by 333
Self-citationGlobal analysis of advanced/metastatic breast cancer: decade report (2005-2015)
Cardoso, F., Spence, D., Mertz, S., Corneliussen-James, D., Sabelko, K., Gralow, J., Cardoso, M.-J., Peccatori, F., Paonessa, D., Benares, A., et al. (2018) · The Breast · doi:10.1016/j.breast.2018.03.002 · Cited by 324 · cited 1×
“INTRODUCTION More than 90% of patients with breast cancer are diagnosed with early-stage disease, of whom approximately 70% have cancers that are hormone receptor positive (HR1) and human epidermal growth factor receptor 2 negative (HER22).(1,2) Standard treatment varies depending on risk of recurrence but includes co…”
BackgroundJohnston, S., Puhalla, S., Wheatley, D., Ring, A., Barry, P., Holcombe, C., Boileau, J. F., Provencher, L., Robidoux, A., Rimawi, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01624 · Cited by 228
Self-citation
Cited by
Loibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Breast cancer: pathogenesis and treatments
Xiong, X., Zheng, L.-W., Ding, Y., Chen, Y.-F., Cai, Y.-W., Wang, L.-P., Huang, L., Liu, C.-C., Shao, Z.-M., & Yu, K.-D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 958
Self-citationBurstein, H. J., Curigliano, G., Thürlimann, B., Weber, W. P., Poortmans, P., Regan, M. M., Senn, H. J., Winer, E. P., Gnant, M., Aebi, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.023 · Cited by 821
Self-citationDeciphering breast cancer: from biology to the clinic
Nolan, E., Lindeman, G. J., & Visvader, J. E. (2023) · Cell · doi:10.1016/j.cell.2023.01.040 · Cited by 730
Johnston, S. R. D., Toi, M., O'Shaughnessy, J., Rastogi, P., Campone, M., Neven, P., Huang, C.-S., Huober, J., Jaliffe, G. G., Cicin, I., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00694-5 · Cited by 599
Self-citation
Metadata
- Authors
- Johnston, S. R. D., Harbeck, N., Hegg, R., Toi, M., Martin, M., Shao, Z. M., Zhang, Q. Y., Martinez Rodriguez, J. L., Campone, M., Hamilton, E., Sohn, J., Guarneri, V., Okada, M., Boyle, F., Neven, P., Cortés, J., Huober, J., Wardley, A., Tolaney, S. M., Cicin, I., Smith, I. C., Frenzel, M., Headley, D., Wei, R., San Antonio, B., Hulstijn, M., Cox, J., O’Shaughnessy, J., Rastogi, P., & on behalf of the monarchE Committee Members and Investigators
- Venue
- Journal of Clinical Oncology
- Published
- 2020-12-01
- Volume
- 38
- Issue
- 34
- Pages
- 3987-3998
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3087501542
- Cited by
- 1,022
- References
- 17
- FWCI
- 58.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.